Querol, L, Lewis, RA, Van Doorn, PA, Hughes, RAC, Storek, M, Rajagopal, V, Chow, T, Luo, XD, Alonso-Alonso, M, Atassi, N, Hartung, HP. PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Fernandez-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Audic, F, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, de la Tassa, GM, Olivé, M, de la Hoz, CPDF, Isapof, A, Töpf, A, Walter, M, Angelini, C, Claeys, K, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Van Doorn, PA, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, K, Hewamadduma, C, Hofman, E, Hussain, Y, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, T, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

González-Saiz, F, Vergara-Moragues, E, Trujols, J, Alcaraz, S, de los Cobos, JP. Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient. INTERNATIONAL JOURNAL OF DRUG POLICY. 2024; 130DOI:10.1016/j.drugpo.2024.104519. PMID:39024687. IF:4.400(Q1/1D).

Clougher, D, Forte, MF, Mezquida, G, Sánchez-Torres, AM, Serra-Navarro, M, Penadés, R, Lobo, A, Pinto, AG, Panadero, R, Roldán, A, Vieta, E, de la Serna, E, Trabsa, A, Martínez-Aran, A, Torrent, C, Tortorella, A, Menculini, G, Ramos-Quiroga, JA, Cuesta, MJ, Bernardo, M, Amoretti, S. Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024; 85DOI:10.1016/j.euroneuro.2024.05.006. PMID:39013243. IF:6.700(Q1/1D).

Corripio, I, Fraguas, D, García-Portilla, MP, Olivares, JM, Sierra, P, Sánchez, P. Functioning in schizophrenia: Recommendations of an expert panel. SCHIZOPHRENIA RESEARCH. 2024; 270DOI:10.1016/j.schres.2024.06.050. PMID:38964076. IF:3.500(Q1/3D).